Trending...
- The Problem With AI Isn't Compute. It's Memory
- Boston: June 5, 2026 Traffic Advisory
- A Foundational Claim in Human Secrecy Goes Public
EBERBACH, Germany, June 9, 2025 /PRNewswire/ -- GELITA, a global leader in pharmaceutical gelatin and collagen peptide solutions, is proud to announce its participation as an exhibitor at BIO International 2025 in Boston. This year's presentation highlights the company's innovative excipients, MEDELLAPRO® and VACCIPRO®, meeting the specific needs of advanced pharmaceutical formulations and medical devices.
GELITA's Endotoxin Controlled Excipients (ECE) portfolio, including MEDELLAPRO® (gelatin) and VACCIPRO® (collagen peptides), addresses the demanding requirements of pharmaceutical and medical applications such as vaccine stabilizers, tissue engineering, 3D bioprinting, implants and advanced wound care. In pharmaceutical, medical device and healthcare environments, endotoxin control is crucial to ensure product safety and patient well-being.
MEDELLAPRO® stands out for its versatility and inherent biocompatibility, making it ideal for applications such as surgical sealants, hemostatic agents, scaffolds, 3D bioprinting and drug delivery systems. Vaccines stabilized with VACCIPRO® show very low allergenic potential, high bioavailability and excellent cell tissue affinity. VACCIPRO® is globally recognized as THE gold standard by vaccine manufacturers.
More on Boston Chron
With a strong commitment to quality and innovation, GELITA continues to empower the pharmaceutical and medical device industries with solutions that drive efficiency and safety in the development of life-saving therapies. GELITA is well advanced in developing biotechnological processes to produce animal-free alternatives with optimized properties that are even more resource-efficient and sustainable than conventional methods. With the pharmaceutical know-how of the GELITA Pharma Institute and GELITA's Biotech R&D Hub, the company is well-equipped to expand its biotechnological expertise and product portfolio
Visit GELITA at Booth 2865-01in the German Pavilion to explore how MEDELLAPRO® and VACCIPRO® are shaping the future of vaccine development and medical devices.
About GELITA
GELITA is one of the leading companies for manufacturing and marketing collagen proteins. Coordinated from headquarters in Eberbach, Germany, GELITA provides customers around the world with products of the highest standard, comprehensive technical expertise and sophisticated solutions. More than 20 sites and a global expert network ensure that state-of-the-art know-how is always available for customers. GELITA's performance is based on 150 years of experience in the field of collagen proteins, and a strong desire for innovation is the driving force of the family-owned company, which is always looking for new solutions for food, pharmaceutical, health & nutrition markets, as well as for technical applications.
More on Boston Chron
Within its range of collagen proteins, GELITA supplies collagen peptides with proven body-stimulating capabilities as well as tailor-made gelatins. This holistic range of products in combination with its vast experience in developing solutions for different applications makes GELITA first choice for customers in every continent. In today's landscape of high consumer demands, manufacturers of food products must rely on natural, healthy, non-allergenic ingredients for successful developments. Collagen proteins from GELITA are the perfect match for this as they fulfill all these requirements, a particular plus being the fact that they are foodstuffs (i.e. no E-number).
SOURCE GELITA
GELITA's Endotoxin Controlled Excipients (ECE) portfolio, including MEDELLAPRO® (gelatin) and VACCIPRO® (collagen peptides), addresses the demanding requirements of pharmaceutical and medical applications such as vaccine stabilizers, tissue engineering, 3D bioprinting, implants and advanced wound care. In pharmaceutical, medical device and healthcare environments, endotoxin control is crucial to ensure product safety and patient well-being.
MEDELLAPRO® stands out for its versatility and inherent biocompatibility, making it ideal for applications such as surgical sealants, hemostatic agents, scaffolds, 3D bioprinting and drug delivery systems. Vaccines stabilized with VACCIPRO® show very low allergenic potential, high bioavailability and excellent cell tissue affinity. VACCIPRO® is globally recognized as THE gold standard by vaccine manufacturers.
More on Boston Chron
- Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
- Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
- Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
- The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
With a strong commitment to quality and innovation, GELITA continues to empower the pharmaceutical and medical device industries with solutions that drive efficiency and safety in the development of life-saving therapies. GELITA is well advanced in developing biotechnological processes to produce animal-free alternatives with optimized properties that are even more resource-efficient and sustainable than conventional methods. With the pharmaceutical know-how of the GELITA Pharma Institute and GELITA's Biotech R&D Hub, the company is well-equipped to expand its biotechnological expertise and product portfolio
Visit GELITA at Booth 2865-01in the German Pavilion to explore how MEDELLAPRO® and VACCIPRO® are shaping the future of vaccine development and medical devices.
About GELITA
GELITA is one of the leading companies for manufacturing and marketing collagen proteins. Coordinated from headquarters in Eberbach, Germany, GELITA provides customers around the world with products of the highest standard, comprehensive technical expertise and sophisticated solutions. More than 20 sites and a global expert network ensure that state-of-the-art know-how is always available for customers. GELITA's performance is based on 150 years of experience in the field of collagen proteins, and a strong desire for innovation is the driving force of the family-owned company, which is always looking for new solutions for food, pharmaceutical, health & nutrition markets, as well as for technical applications.
More on Boston Chron
- Boston to Join Bloomberg Philanthropies' National Initiative To Connect Students With High-Wage Careers In Skilled Trades
- Boston: $200,000 In Small Business Grants Announced Ahead of Summer Events
- Boston: Mayor Wu Announces Extension of Operating Hours for Bars and Restaurants During Summer 2026
- Boston: Mayor Michelle Wu, Secretary Phil Eng Announce Extension of Fare-Free Transit Program
- $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
Within its range of collagen proteins, GELITA supplies collagen peptides with proven body-stimulating capabilities as well as tailor-made gelatins. This holistic range of products in combination with its vast experience in developing solutions for different applications makes GELITA first choice for customers in every continent. In today's landscape of high consumer demands, manufacturers of food products must rely on natural, healthy, non-allergenic ingredients for successful developments. Collagen proteins from GELITA are the perfect match for this as they fulfill all these requirements, a particular plus being the fact that they are foodstuffs (i.e. no E-number).
Media Contact: Amy Maggio [email protected] 312-617-6248 | Company Contact: Martin Junginger (Senior Expert Global Category Management Pharma & Bioscience) GELITA AG +49 6271 84 2103 [email protected] |
SOURCE GELITA
0 Comments
Latest on Boston Chron
- Boston: Community Voices Inform Proposed Monument Square Landmark District
- Boston: Balancing Preservation and Growth in Brighton's Aberdeen District
- Bringing Dorchester's "Lost" 17th- century Capen House Back to Boston
- Boston City Council Approves $8.15 Million in FY2026 Community Preservation Historic Preservation Grants
- Boston: Proposed Demolition (Article 85, Demo Delay) 5 Ashland Street, Dorchester
- KIDZONET & Ocean Telecom Launch UK First eSIM Child Protection — EasySim AI Safe SIM Cards
- School Dental Screening Programs Conducted in Dubai
- British Brand Daniel Mason™ Expands Premium Braided Leather Belt Collection Internationally
- Looking for expert pool tiling in Gold Coast? Call Avid Tiling
- Hosted Network Powers National Growth with netElastic vBNG, CGNAT and netVision
- RAIN Group to Preview Top Sales Challenges of 2026 in Webinar on Conversion and Growth
- Boston Acquisition Fund Preserves 43 Affordable Homes in Roslindale
- Super Lawyers Recognizes Inman & Tourgee Attorneys Mark Tourgee and Jacob Rinn
- PropAccount.com Launches PropGenie, the First Branding Studio Built for Prop Firm Operators
- Rushing Headlong: Health IT's Legacy and the Road to Responsible AI is named 2025 Foreword INDIES Book of the Year Awards Winner
- The Problem With AI Isn't Compute. It's Memory
- Golden Visa Countries Outpace Eurozone Growth Over Eight Years, New La Vida Analysis Finds
- Allstream Energy Partners Announced as Official Media Partner for the 2nd Annual Permian Power Conference
- Boston Ranked #1 U.S. City for Foreign Investment by Financial Times and Nikkei
- CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing